Citron Takes Aim at Mallinckrodt, Blasts Acthar Gel Medication
'Express Scripts has finally changed its stance on Acthar and the effect will send shares of Mallinckrodt to zero,' Citron said.

Shares of Mallinckrodt (MNK) were falling by 8.3% to $39.10 on heavy trading volume on Monday morning, after short seller Citron Research issued a new report criticizing the pharmaceutical company.

Citron went after the company's H.P. Acthar Gel, which is used to treat a variety of conditions, and the enormous price increases that have brought the drug up to almost $40,000 per vial.

Citron attacked Mallinckrodt's partnership with Express Scripts (ESRX) , liking it to the role specialty prescription company Philidor played for embattled pharma company Valeant (VRX) .

"While Express Scripts was supposed to protect the healthcare system from gouges like Acthar, they were actually distributing the drug through their CuraScript division," Citron claims.

However, now Express is changing its tune on Acthar Gel, claiming that the drug is overpriced and poor quality.

"Express Scripts has finally changed its stance on Acthar and the effect will send shares of Mallinckrodt to zero," Citron said.

Jim Cramer and Real Money columnists discuss the latest from President Donald Trump and the GOP's efforts to repeal and replace the Affordable Care Act. See which stocks they are discussing and get his insights or analysis with a free trial subscription to Real Money.

More from Stocks

Market Movers: Tech Earnings

Market Movers: Tech Earnings

Cloud Gaming Adds Growth Opportunity for Microsoft

Cloud Gaming Adds Growth Opportunity for Microsoft

Dow Dives Sharply on Rates Fears, Tech Shares Sink Nasdaq

Dow Dives Sharply on Rates Fears, Tech Shares Sink Nasdaq

Throwback Thursday: To Trade or Not to Trade Paypal

Throwback Thursday: To Trade or Not to Trade Paypal

Daimler's Going Autonomous With Nvidia to Take On Uber, Ride-Hailing Race

Daimler's Going Autonomous With Nvidia to Take On Uber, Ride-Hailing Race